Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia
- 305 Downloads
Background Oral anticoagulant therapy is indicated for the prevention of stroke or other thromboembolic events. Premature discontinuation of oral anticoagulants may increase the risk of thromboembolism resulting in adverse sequelae. There are sparse data on the prevalence and the predictors of dabigatran discontinuation in Malaysian patients with atrial fibrillation. Objectives Determine the reasons and identify associated factors for abrupt discontinuation of dabigatran, assess the switching pattern and the occurrence of thromboembolic events after dabigatran discontinuation. Setting A university-affiliated tertiary hospital in Kuala Lumpur, Malaysia. Methods The clinical and demographic data of a cohort who were initiated with dabigatran between 2010 and 2012 at the University of Malaya Medical Centre were reviewed until the date of death or on 31st December 2013. Those patients who discontinued dabigatran were further followed up until 31st December 2015 to determine the occurrence of any thromboembolic event. Main outcome measure Permanent discontinuation of dabigatran for more than 8 weeks. Results 26 (14 %) of a cohort of 192 patients discontinued dabigatran therapy during a median follow-up period of 20 (range 3–45) months. About one-half of the discontinuation occurred within the first 6 months of dabigatran use. The three most cited reasons for discontinuation are bleeding events (19 %), high out-of-pocket drug payment (19 %) and cardioversion (19 %). Heart failure [adjusted odds ratio 3.699 (95 % confidence interval 1.393–9.574)] or chronic kidney disease [adjusted odds ratio 5.211 (95 % confidence interval 1.068–23.475)] were found to be independent risk factors for abrupt dabigatran discontinuation. Patients who discontinued dabigatran received warfarin (38 %), antiplatelet agents (16 %) or no alternative antithrombotic therapy (46 %). Five of the 26 patients who discontinued dabigatran developed an ischaemic stroke within 3–34 months after discontinuation. Conclusion Abrupt dabigatran discontinuation without an alternative oral anticoagulant increases the risk of thromboembolic events. As adverse drug events and renal impairment contribute substantially to the premature discontinuation of dabigatran, it is important to identify and monitor patients at risk to reduce dabigatran discontinuation rate especially during the first six months of dabigatran therapy.
KeywordsAtrial fibrillation Dabigatran Discontinuation Malaysia DOAC Stroke prevention
We would like to thank all the staff of Patient Information Services and Medical Records Office of the University of Malaya Medical Centre for facilitating the access to the medical records of the patients. We are also grateful to the reviewers and the editors of The International Journal of Clinical Pharmacy for their constructive comments and helpful suggestions.
Conflicts of interest
- 7.Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385–413.CrossRefPubMedGoogle Scholar
- 8.January CT, Wann LS, Alpert JS, Field ME, Calkins H, Murray KT, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–104.CrossRefPubMedGoogle Scholar
- 14.R Core Team [Internet].Vienna (Austria). R: A language and environment for statistical computing. R Foundation for Statistical Computing. Version 3.1.2. 2014, [cited 2015 Dec 30]. Available from: http://www.R-project.org/.
- 15.Therneau T [Internet]. A package for survival analysis in S. R package version 2.37-7. 2014, [cited 2015 Dec 30]. Available from: http://CRAN.R-project.org/package=survival.
- 21.Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:177–9.CrossRefPubMedGoogle Scholar